Alacrita is a transatlantic life science consulting firm providing services to the pharmaceutical, biotechnology and life science sectors. We create value for our clients by forming high-powered project teams.
Dr Rob JohnsonPartner
Mr Paul RennertConsultant
BioPartner UK is an independent UK trade organisation, working with government and private agencies to promote UK expertise and provide practical support for those trading overseas.
Alacrita is your point-of-contact for the UK delegation at BioPharm America 2014.
BrainWave Discovery specialises in the rapid development of in vivo brain assays for chemicals acting on human CNS targets selected by our clients. We use our expertise in "humanising" transgenic fruit flies (Drosophila) to deliver the desired human molecule to a specified subset of nerve cells in the insect brain.
Mr Matt MahoneyDirector, Business Development
Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.
BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.
Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.
CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.
Further information on CNS can be found at www.clinical.net.au
Mr Paul CroninDirector, Business Development
Ms Megan HillBusiness Development Manager
Liftstream provides executive search services and interim management resource to businesses operating in the area of life sciences.
The life sciences market demands the very highest professional capability and acumen in the people it employs, from scientific functions oriented towards research, discovery and development of transformational bioscience and medical technologies, through to their commercialisation.
Liftstream’s executive search recruitment practice brings together unparalleled levels of market research, people engagement and deep client understanding to recruit and employ the right people for the life science clients we represent.
Executive Search in Life Sciences
Interim management is a growing feature of the life sciences sector as it offers access to the very specific skills and experience demanded by particular projects or company strategies. Liftstream offers highly selected interim management professionals from the management and executive levels of life sciences, across most central functions.
Interim Management in Life Sciences
Bringing compatible people together in an environment and culture from which they can mutually benefit and develop remains the primary function of Liftstream. At Liftstream we believe individuality makes our role all that more vital and so we've engendered a culture where relationships are of primary importance and people's unique career or recruitment requirements are the centre of our focus across the respective areas of life sciences.
Mr Karl SimpsonChief Executive Officer
Integrated drug discovery - hit identification, lead generation and lead optimisation using medicinal chemistry, computational chemistry and in vitro biology. Through long-term strategic alliances we incorporate X-ray crystallography, ADME/tox, in vivo PK, and in vivo disease models. Experience across a wide range of disease areas, such as respiratory, oncology and CNS, and biological targets, e.g. kinases, GPCRs, PPIs, NHRs & epigenetics. Clients located in the USA, Europe and Australasia.